Results 121 to 130 of about 98,309 (302)

Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley   +1 more source

CD20 [PDF]

Science-Business eXchange, 2011
openaire   +2 more sources

Clinical Images: A thorn injury, a sea‐borne culprit, and a tenosynovitis dilemma

Arthritis &Rheumatology, EarlyView.
Jacopo Ciaffi, Francesco Mori, Paolo Sassu, Marco Gambarotti, Alberto Righi, Eleonora Zamparini, Marco Innocenti, Marina Tadolini, Francesco Ursini   +8 more
wiley   +1 more source

DinoFlow: Self‐supervised pretraining in flow cytometry enables accurate detection of common hematopathological disorders

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Flow cytometry is an essential component of routine hematological lab testing. Many computational methods have been proposed for the analysis of flow cytometry data, but most have focused on supervised learning for just one or a few specific disorders.
Brendan O'Fallon, Muir Morrison, Mattia Medina Grespan, Nicholas C. Spies, David P. Ng   +4 more
wiley   +1 more source

Strong CD20 Positivity

, 2013
DLBCL usually expresses various pan-B markers, e.g. CD20 and CD79a.
Catherine Burton (10254)
core   +1 more source

Challenges and Pitfalls to Diagnosing NUTM1‐Rearranged Neoplasia of the Pancreas by Cytology and Ancillary Studies

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fine‐needle aspiration cytology specimens are frequently utilized for ancillary studies to identify diagnostic and prognostic information. This case highlights diagnostic pitfalls and challenges in diagnosing NUTM1‐rearranged neoplasia on pancreatic cytology.
Terrance J. Lynn
wiley   +1 more source

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: Implications for cellular immunotherapy of CD20+ malignancy

, 1998
The CD20 molecule was evaluated as a B-cell lymphoma target epitope for T cells expressing a CD20-specific single-chain FvFc-zeta (scFvFc:zeta) chimeric receptor.
Jensen, Michael, Tan, Giselle, Raubitschek, Andrew, Wu, Anna M, Forman, Stephen   +4 more
core   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial

Frontiers in Medicine
IntroductionAlthough rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies.
Miriam M. Moser, Renate Thalhammer, Christian Sillaber, Ulla Derhaschnig, Christa Firbas, Ulrich Jäger, Bernd Jilma, Christian Schoergenhofer   +7 more
doaj   +1 more source

CD20 role in pathophysiology of Hodgkin’s disease

, 2017
Summary Hodgkin’s lymphoma (HL) is a tumor comprising non-malignant and malignant B-cells. Classical HL expresses CD15+ and CD30+ antigens, and 20 to 40% of patients are CD20+.
Marcelo Antônio Oliveira Santos, Marinus de Moraes Lima   +1 more
core   +1 more source